Susanne Meline - 09 Jan 2023 Form 4 Insider Report for Ra Medical Systems, Inc. (VTAK)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
27 Mar 2023, 17:22:02 UTC
Prior SEC filing
04 Jan 2023
Next SEC filing
02 Aug 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Susanne Meline

Key filing fact

Susanne Meline filed Form 4 for Ra Medical Systems, Inc. (VTAK) on 27 Mar 2023.

Key facts

  • This page summarizes Susanne Meline's Form 4 filing for Ra Medical Systems, Inc. (VTAK).
  • 3 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 27 Mar 2023, 17:22.

Change

  • Previous filing in this sequence was filed on 04 Jan 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RMED transaction

Common Stock

Conversion of derivative security

Transaction value
$0
Shares
+2,575
Change %
Price
$0.000000
Shares after
2,575
Date
23 Mar 2023
Ownership
By Spouse
Footnotes
F1
RMED holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
36
Date
09 Jan 2023
Ownership
Direct
RMED holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
800
Date
09 Jan 2023
Ownership
See footnote
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RMED transaction Derivative

Series X Convertible Preferred Stock

Award

Transaction value
$0
Shares
+14
Change %
Price
$0.000000
Shares after
14
Date
09 Jan 2023
Ownership
By Spouse
Underlying class
Common Stock
Underlying amount
14,056
Exercise price
$0.000000
Footnotes
F3, F4, F5
RMED transaction Derivative

Series X Convertible Preferred Stock

Conversion of derivative security

Transaction value
$0
Shares
-3
Change %
-18%
Price
$0.000000
Shares after
11
Date
23 Mar 2023
Ownership
By Spouse
Underlying class
Common Stock
Underlying amount
11,481
Exercise price
$0.000000
Footnotes
F1, F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

This the transaction was the result of the automatic conversion of shares of Series X Preferred upon receipt of stockholder approval.

Footnote F2

Securities are owned by Catalysis Partners ("CP"). The reporting person has an investment interest in CP through her IRA and, together with an immediate family member, owns a controlling interest in Francis Capital Management, LLC, which also has an investment interest in CP and serves as both its Managing Member and Investment Manager. The reporting person disclaims beneficial interest of these securities except to the extent of her pecuniary interest therein.

Footnote F3

Following stockholder approval of the conversion of Series X Convertible Preferred Stock into shares of Common Stock, each share of Series X Convertible Preferred Stock automatically converts into 1,000 shares of Common Stock, subject to certain limitations.

Footnote F4

On January 9, 2023, the Issuer, completed its acquisition of Catheter Precision, Inc., a privately-held Delaware corporation ("Catheter"), pursuant to an Amended and Restated Agreement and Plan of Merger (the "Merger"). In connection with the Merger, each share of Catheter common stock previously outstanding held by the reporting person now represents a number of shares of Series X Convertible Preferred Stock equal to approximately 0.6697, divided by one thousand (1,000).

Footnote F5

Series X Convertible Preferred Stock has no expiration date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .